This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Amiodarone
Description: The precise mechanism of action of Cordarone (amiodarone) is unknown.
Cordarone is primarily a class III antiarrhythmic (see below), but also has class I, II, and IV effects. Among other things, it slows conduction and prolongs the refractoriness of tissue to a new electrical impulse. It has both an IV and oral formulation, which differ in some electrophysiological effects. The specific currents/receptors it blocks are: INa, ICaL, ICaT, IKr, Iks, IKATP, IKAch, If, and beta1R.
The Vaughan Williams Classification is as follows: I (blocks sodium channel; subclasses based on their effect on action potential duration), II (blocks beta-adrenergic receptors), III (blocks potassium efflux), IV (blocks L-type calcium channels, affecting conduction through the AV node between the upper and lower chambers of the heart), V (other).
Deal Structure: Cordarone was originally developed by sanofi and Wyeth.
The marketing exclusivity for Cordarone I.V. ended on October 11, 2002.
In January 2009, Pfizer and Wyeth announced that they entered into a definitive merger agreement under which Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at $50.19 per share, or a total of approximately $68 billion. The acquisition was completed in October 2009.
Partners: Pfizer Inc.
Pink Sheet In Brief: Wyeth-Ayerst's Cordarone IV
Pink Sheet In Brief: Wyeth-Ayerst's I.V. Cordarone
Additional information available to subscribers only: